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ABSTRACT
Background Community management of atrial fibrillation 
(AF) often requires the use of electrocardiographic (ECG) 
investigation. Patients discharged following treatment of 
AF with fast ventricular response (fast AF) can require 
numerous ECGs to monitor rate and/or rhythm control. 
Single- lead ECGs have been proposed as a more 
convenient and relatively accurate alternative to 12- lead 
ECGs for rate/rhythm management and also diagnosis 
of AF. We aimed to examine the feasibility of using the 
AliveCor single- lead ECG monitor for diagnosis and 
monitoring of AF in the community setting.
Methods During the course of 6 months, this evaluation 
of a clinical service improvement pathway used the 
AliveCor in management of patients requiring (1) follow- up 
ECGs for AF with previously documented rapid ventricular 
rate or (2) ECG confirmation of rhythm where AF was 
suspected. Twelve AliveCor devices provided to the acute 
community medical team were used to produce 30 s ECG 
rhythm strips (iECG) that were electronically sent to an 
overreading physician.
Results Seventy- four patients (mean age 82 years) 
were managed on this pathway. (1) The AliveCor was 
successfully used to monitor the follow- up of 37 patients 
with fast AF, acquiring a combined total of 113 iECGs 
(median 1.5  ± 3.75 per patient). None of these patients 
required a subsequent 12- lead ECG and this approach 
saved an estimate of up to £134.49 per patient. (2) Of 53 
patients with abnormal pulses, the system helped identify 
8 cases of new onset AF and 19 cases of previously known 
AF that had reverted from sinus back into AF.
Conclusions We have demonstrated that the AliveCor 
system is a feasible, cost- effective, time- efficient and 
potentially safer alternative to serial 12- lead ECGs for 
community monitoring and diagnosis of AF.
INTRODUCTION
Atrial fibrillation (AF) is a spectrum of 
disease and affects around 5.5% of adults 
aged 55 years and over.1 It can be either 
paroxysmal, persistent or permanent, and 
although some patients may be asympto-
matic, it is often associated with symptoms 
such as palpitations, breathlessness, fatigue 
and reduced exercise capacity. Patients 
with symptomatic AF are treated with either 
a rate or rhythm control strategy. Rate 
control is often the first- line approach for 
AF with an onset of greater than 48 hours, 
and can be achieved with acute and then 
long- term use of beta- blockers, calcium 
channel blockers, cardiac glycosides or 
combination therapy. Beta- blockers are 
considered first- line long- term therapy for 
patients with persistent or permanent AF 
and symptoms related to rapid ventricular 
rate (fast AF) for symptomatic relief. 
Community follow- up monitoring is neces-
sary to guide effective treatment. Conven-
tionally, 12- lead ECGs have been used, but 
the advent of reliable single- lead ECGs with 
accurate built- in AF detection algorithms 
have the potential to streamline this moni-
toring process.
Single- lead ECGs could also have a role 
in community detection of AF. A diag-
nosis of AF can be difficult to make in the 
community as up to 62% is paroxysmal and 
up to 40% is asymptomatic.2 3 In the UK, 
AF is detected through opportunistic inves-
tigation as systematic screening is currently 
Strengths and limitations
 ► This is the first pilot initiative to demonstrate the 
feasibility of using a structured algorithm to facilitate 
the integration of single- lead ECGs into community 
monitoring and diagnosis of atrial fibrillation (AF).
 ► The AliveCor is US Food and Drug Administration ap-
proved and NICE evaluated, and therefore has the 
potential for wider integration into community AF 
management.
 ► The sample size is small, and the study is conducted 
in a single health board.
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not recommended by the UK National Screening 
Committee predominantly due to a lack of outcome 
evidence.4 Detection is important because new- onset 
AF is thought to account for one- fifth of patients 
hospitalised for ischaemic stroke.5 Indeed, AF is a 
well- established independent risk factor of ischaemic 
stroke,6 with convincing evidence for direct causality.5 
Having controlled for confounding, device- detected 
AF lasting at least 1 hour in 3 months (0.046% of the 
time) is associated with a 2.11- fold increase in stroke 
risk compared with no AF.7 Anticoagulation in the form 
of direct oral anticoagulants or adjusted- dose warfarin 
reduces stroke risk by over 60%.8 NICE recommends 
anticoagulation in moderate- to high- risk patients.9
Previously, when ECG investigation had been 
required, our Acute Community Team in the Neath 
Port Talbot area have had to rely on undertaking a 
12- lead ECG in the community. This can be a cumber-
some and lengthy process that risks inappropriate 
tachyarrhythmia management, missed or delayed diag-
nosis of paroxysmal AF with adverse implications for 
initiation of appropriate anticoagulation. There is 
mounting evidence for the utility of integrating single- 
lead ECGs into healthcare provision in a number of 
settings.10–16 This pilot initiative aimed to test the 
feasibility of integrating a single- lead hand- held ECG 
system, the AliveCor, into community monitoring of 
treatment in patients with recently diagnosed fast AF 
and opportunistic community diagnosis of AF.
METHOD
Participants and setting
This evaluation of a clinical service improvement pathway 
enrolled a total of 74 patients from the Neath Port Talbot 
community between June and November 2017. Partic-
ipants were eligible for inclusion if patients had been 
referred to the Acute Community Team with (1) known 
fast AF requiring monitoring and management, and (2) 
suspected AF due to an abnormal pulse on manual pulse 
check. There were no specific exclusion criteria. Baseline 
characteristics are recorded in table 1.
Patient and public involvement
When asked, patients have expressed similar thoughts 
around the cumbersome nature of obtaining 12- lead ECG 
monitoring. Patients were involved at the stage of results 
collection. After providing informed verbal consent, 
patients were encouraged by the Acute Clinical Team to 
provide feedback on use of the AliveCor, which contrib-
uted to our results and discussion section.
Single-lead ECG device (AliveCor—KardiaMobile)
The AliveCor Kardia Mobile system (AliveCor, Moun-
tain View, CA) consists of a battery- powered pair of 
electrodes and a Smartphone- based application linked 
using ultrasonic audio.17 The iECGs produced are a 30 s 
single- lead rhythm strip likened to lead 1 of a 12- lead 
ECG. iECGs can be input into accurate automatic algo-
rithms (sensitivity 98%, specificity 97%) to detect AF.18 It 
is possible to store multiple iECGs and send them using 
WiFi securely to a physician. In this initiative, a local 
experienced academic clinical staff member trained the 
Acute Community Team members in using the AliveCor. 
Twelve AliveCor devices were provided to the commu-
nity teams.
Community atrial fibrillation monitoring
Hospital discharges of newly treated AF with rapid 
ventricular response were referred to the Acute Commu-
nity Team for ECG monitoring to ensure appropriate rate 
or rhythm control. Figure 1 shows how in the situation 
where a 12- lead ECG was not available, the AliveCor was 
used to direct optimised medical therapy. We recorded 
the number of iECGs required per patient and whether 
any further 12- lead ECG monitoring was required after 
use of the AliveCor (figure 2).
Community atrial fibrillation diagnosis
As demonstrated in figure 3, patients with symptoms 
consistent with AF were referred to the Acute Community 
Team for an initial clinical assessment. If the rhythm of 
the pulse was ‘abnormal’ or if the patient reported palpi-
tations at the time of assessment, an ECG would be neces-
sary. The AliveCor device was used if a 12- lead ECG was 
not immediately available. Had the use of the AliveCor 
not been possible, ambulatory Holter monitoring would 
have been arranged. We recorded the number of patients 
found to be in AF, and other rhythm disorders as inter-
preted by a cardiologist (table 2).
Cost-effectiveness
In 2019, NICE estimated the cost of a 12- lead ECG with 
either general practitioner (GP) or cardiologist overread 
to be between £12.34 and £5219 and each AliveCor device 
to cost £62.49+VAT.20
Table 1 Patient characteristics
Diagnosis Rate control monitoring Included participant overall average
Participants (n) 53 37 90
Mean age (years) 78.7 79.8 81.6
Sex (% female) 80 73 77
Patient characteristics for each group studied. The diagnosis group pertains to participants investigated for an abnormal pulse or symptoms 
consistent with AF and the monitoring group are participants followed up for optimal medical rate or rhythm control.
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Statistics
Descriptive statistics were calculated and graphical data 
were presented using IBM SPSS V.26. OriginPro 2019b 
was used to construct the bar graph (figure 2).
Ethical considerations
According to WHO and Healthcare Quality Improve-
ment Partnership guidance, risk–benefit analysis was 
performed internally. The proposal was deemed to be a 
‘patient safety activity’ as the AliveCor was used within a 
standard of care framework, the approach was tailored 
to improving provision of care in Swansea Bay University 
Health board, and the initiative did not involve vulnerable 
populations. The patient safety activity was considered of 
‘minimal risk’ as it did not change treatment plans, data 
were not individually identifiable, the intervention did 
not divert staff from existing responsibilities and imple-
mentation did not constitute an elevated level of risk to 
patients or staff.
RESULTS
Baseline characteristics of the total 74 participants 
recruited (n=37 monitoring, n=53 diagnosis) can be 
found in table 1. Participants were a mean age of 81.3 
years and were predominantly female (female:male, 
54:20). No participants were lost to follow- up.
Community atrial fibrillation monitoring
The 37 patients requiring ECG monitoring for follow- up 
of fast AF, required a total of 113 iECGs (median 1.5  ±
 3.75 per patient). The majority of patients only required 
one follow- up iECG to confirm adequate rate or rhythm 
control (figure 2). However, some patients required up 
to 10 iECGs to titrate medication dose to appropriate 
clinical effect. There were no cases in which a 12- lead 
ECG was required due to the single- lead ECG not being 
sufficient. In terms of cost- effectiveness, assuming a 
12- lead ECG would have been performed where in our 
initiative an iECG was required, the 12 AliveCor devices 
saved between £495 and £4976 according to NICE 2014 
estimates, depending on GP or cardiologist overread.19 20 
This equates to an average of £13.37 and £134.49 per 
patient requiring follow- up ECG monitoring.
Community atrial fibrillation diagnosis
Of the 53 patients assessed, 8 were found to have new- 
onset AF, 19 patients with known AF (noted to be in sinus 
rhythm prior to index assessment) were found to have 
reverted back to AF, 7 had ‘other’ ECG abnormalities and 
19 were normal (table 2). Of the eight patients found to 
have new onset AF, five were female, with an average age 
of 78.3 years (SD ±7.1 years) and an average CHA2DS2- 
VASc score of 4.9 (SD ±0.85, range 3–6). All agreed to 
be appropriately anticoagulated. We found that as iECGs 
could be easily uploaded via a secure internet connection, 
they could be overread by a physician in an appropriately 
timely manner.
DISCUSSION
This single health board clinical service improvement 
pathway evaluation included 74 participants over a 
6- month period using the US FDA–approved AliveCor. To 
our knowledge, this is the first pilot initiative to demon-
strate the feasibility of using a structured algorithm to 
facilitate the integration of single- lead ECGs into commu-
nity monitoring and diagnosis of AF. We found that the 
Figure 1 AF monitoring—patient flow for participants 
referred with fast AF or whom develop fast AF while under 
the care of the ACT. ACT, Acute Community Team; AF, atrial 
fibrillation; GP, general practitioner.
Figure 2 Histogram showing the number of iECGs per 
patient taken over a 6- month period.
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AliveCor device was easy to use, more time- effective and 
cost- effective, and successfully prevented the need for 
serial 12- lead ECGs in the community. Of the 37 patients 
requiring ECG monitoring, 113 iECGs were needed and 
of the 53 patients with an ‘abnormal’ pulse, 15% were 
found to be in new- onset AF and were appropriately anti-
coagulated.
There are a number of commercially available portable 
ECG devices which are suitable for out- of- hospital 
use, ranging from one- lead to three- lead ECG devices. 
Portable ECGs have the advantage that they are easy to 
carry, relatively lightweight and low cost. The advantages 
of the AliveCor system is that it is (1) immediately acces-
sible as an iECG, (2) portable, (3) user- friendly due to a 
filter for noise reduction and (4) is US Food and Drug 
Administration (FDA) approved and NICE evaluated.20 
A recent meta- analysis by Duarte and colleagues exam-
ined the diagnostic accuracy of single- lead ECGs in four 
studies in asymptomatic individuals by a cardiologist or 
electrophysiologist and found a sensitivity of 93.9% (95% 
CI 86.2% to 97.4%) and a specificity of 96.5% (95% CI 
90.4% to 98.8%) for diagnosing AF,21 which is consid-
erably superior to manual pulse palpation (specificity 
78.8%, 95% CI 51.0% to 94.5%).22
The AliveCor is the most widely studied single- lead ECG 
device, but there are other examples such as the Omron 
HeartScan23 or the Zenicor ECG24 which do not require 
smartphones. There are also wearable three- lead ECGs 
Figure 3 AF diagnosis—patient flow for patients with symptoms consistent with AF or an ‘abnormal pulse’ on palpation. ACT, 
Acute Community Team; AF, atrial fibrillation; GP, general practitioner.
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such as the ZioPatch25 and the Nuvant mobile cardiac 
telemetry.26 Three- lead ECGs appear to be comparable 
with single- lead ECGs when assessing most intervals27; 
however, they do require longer application periods to 
obtain true readings and there can be a greater delay in 
accessing and reporting the ECG data.25
Integration of single- lead ECG devices into existing 
pathways has been demonstrated to be feasible in primary 
care,10 11 opportunistically in pharmacies,12 13 in low- 
resource settings,14 in rural areas15 and on a large scale.16 
Similarly to our findings, all of these studies found a high 
degree of successful operator use. Six of these studies 
comment on uninterpretable traces and describe low 
rates with an average of 0.82% (SD ±0.52%, range 0% 
to 1.3%). All of these studies report at least one training 
session as being sufficient for operators. In comparison 
with 12- lead ECGs, Holter monitoring and invasive event 
recorders, single- lead ECGs only require finger contact. 
Moreover, iECGs are designed to be transferred, analysed 
and stored. Once the application is set up, the system is 
relatively straightforward. Indeed, the vast majority of 
patients also appear to find the device easy to use.28
Limitations and challenges 
To further evaluate the incorporation of single- lead ECGs 
into community AF diagnosis and monitoring pathways, 
this design can be extended to other health boards, 
increased in duration and participant number. Use of the 
AliveCor KardiaMobile was particularly valuable if there 
was a lack of time or if patients preferred not to undress 
for a 12- lead ECG. It was not difficult to obtain a trace 
with help, even in patients with poor dexterity or cogni-
tive impairment. One of the main challenges encoun-
tered by the team was WiFi connectivity when out in the 
community on home visits. This meant that the clinical 
staff sometimes had to wait for a WiFi signal to resume 
before upload of iECGs was possible. With regard to docu-
mentation, particular care was taken to ensure traces were 
named. This was less of an issue with the online platform 
which comes with the AliveCor device (The Kardia Pro 
system). We collected verbal instead of written consent 
for inclusion, which limited our collection of patient data.
Cost-effectiveness
Another potential barrier to the integration of oppor-
tunistic use of single- lead ECGs in the National Health 
Service (NHS) is cost- effectiveness. The AliveCor appears 
to be a sustainable solution in the follow- up of AF with 
fast ventricular response as we saved an average of £13.37 
to £134.49 per patient. Cost- effectiveness of single- lead 
ECGs have been demonstrated in similar circumstances. 
The multicentre, randomised trial (n=243) by Reed and 
colleagues investigated the use of the AliveCor during 
symptoms over a 90- day period as opposed to ambula-
tory ECG monitoring.29 They found the AliveCor device 
saved £474 per patient compared with standard care. 
Moreover, Duarte and colleagues have estimated the cost- 
effectiveness of using single- lead ECGs in a primary care 
setting compared with routine, opportunistic AF detec-
tion using manual pulse palpation.21
Ongoing benefits
We found that use of the AliveCor in the community cut 
down the number of patients needing to return to clinic. 
Moreover, the AliveCor is now used by our community 
team’s clinicians in the field and also in clinic to quickly 
assess and confirm a patient’s cardiac rhythm.
CONCLUSION
This initiative demonstrated the feasibility of integrating 
single- lead ECGs into NHS provision of community health-
care for patients with AF. We found that the AliveCor was 
a useful clinical adjunct to standard care as it provides 
an accurate, point- of- care elucidation of patient rhythm, 
saving valuable time and money in the delivery of acute 
community medical services.
Contributors JJHB is responsible for data formulation, data analysis, figure design, 
literature review, writing the original manuscript, editing the final manuscript and 
project administration. EFL is responsible for contributing to data formulation, 
figure design, contributing to writing the original manuscript and editing the final 
Table 2 Diagnoses using single- lead iECGs
Month Number Normal New AF Known AF, found to be in AF Other
June 9 5 1 2 1 tachycardia
July 9 3 0 4 1 tachycardia
1 atrial ectopy
Aug 5 0 1 2 1 bradycardia
1 tachycardia
Sept 14 2 3 7 1 tachycardia
1 atrial ectopy
Oct 12 7 2 3 –
Nov 4 2 1 1 –
Total 53 19 8 19 7
Distribution of findings using the AliveCor device for patients with an abnormal pulse or symptoms of atrial fibrillation (AF).
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